마지막 업데이트: 2026년 8월 15일

A large part of my clinic is men who arrived with one number on a health-check report: a PSA above the 4.0 ng/mL cutoff. They are frequently very frightened by the time they sit down, and much of the consultation is spent explaining what that number does and does not mean. So let me start where I start with them.

An elevated PSA usually does not mean cancer. It means the prostate has leaked more of one particular enzyme into the blood than expected — and there are several ordinary reasons for that.

What PSA actually is

PSA stands for Prostate Specific Antigen, an enzyme made only by the prostate, whose job is to liquefy semen after ejaculation. It sits at high concentration inside prostate tissue and at very low concentration in the bloodstream. Anything that disturbs prostate tissue — an enlarged prostate, infection, or even minor manipulation of the gland — lets PSA leak into the blood and pushes the number up. When that happens without cancer being present, we call it a false positive.

Note what the name does 아니 say: PSA is prostate-specific, not cancer-specific. That single distinction explains most of what follows.

Illustration of the prostate gland, the only source of PSA in the blood
PSA is specific to the prostate — but not specific to prostate cancer.

Why screening everyone is no longer recommended

In 2018 a landmark US review concluded that universal PSA screening is not right for everyone: a modest benefit in men aged 55–69, and no benefit in men aged 70 and above. The reasoning is worth understanding rather than just accepting.

Put plainly: screening can save a life, and it can also cause harm to a man who was never going to be harmed by his cancer. That is the trade-off, and it is why the recommendation is a conversation rather than a rule.

A blood sample being taken for a PSA test
PSA needs nothing more than a blood sample — the difficulty lies in interpreting it.

Who should start the conversation earlier

The 55–69 window applies to men at average risk. Some men are not at average risk and should raise it sooner, at around 40–45:

One thing that has changed since 2018

Much of the harm in the list above comes from the assumption that a raised PSA leads more or less automatically to a needle biopsy. That is no longer the case. MRI of the prostate before biopsy can distinguish suspicious areas from an innocent gland, and spares a substantial proportion of men a biopsy they did not need. Where a biopsy is still required, the MRI-fusion transperineal technique targets the suspicious area rather than sampling blindly.

This matters for your decision: the balance of benefit and harm in a 2018 review reflected the pathway as it was then, and the harm side of that equation is smaller now than it was.

So what should you do?

If you are a man aged 55–69, discuss PSA screening with your doctor and reach a decision together, in the light of your own risk and your own view of the trade-off. It is genuinely your choice — there is no single right answer that applies to every man, which is exactly why the guidance stops short of telling you what to do.

And if you have already had a high result, do not panic before you have the full picture: here is what a high PSA actually means and what happens next. Screening is also only worth doing if effective treatment follows a positive result — you can read what that treatment involves on the prostate cancer surgery service page.

PSA 선별 검사에 대한 질문이 있거나 PSA 수치가 높다는 결과를 받으셨다면, Soarawee Weerasopone 박사가 방콕 병원 본원에서 전문 상담을 제공합니다. 진료 예약. 사미즈 시라차 병원 예약은 비뇨기과로 전화하여 하실 수 있습니다. 088-022-1445.

PSA 선별 검사에 대한 자주 묻는 질문

PSA 검사는 무엇이며 무엇을 감지합니까?

PSA (Prostate Specific Antigen) is a blood test that measures the level of an enzyme produced by the prostate gland. Elevated PSA may indicate prostate cancer, but it can also be raised by benign conditions such as BPH, prostatitis, or even minor prostatic manipulation. PSA is prostate-specific, not cancer-specific. It is used as a screening tool for prostate cancer, particularly in men aged 55–69, but must be interpreted carefully in context with other clinical information.

모든 사람이 PSA 검사를 받아야 하나요?

아니요. 현재 증거는 보편적인 PSA 검사를 지지하지 않습니다. 2018년 미국의 중요한 연구에 따르면 55세에서 69세 남성에게는 약간의 이익이 있었지만, 70세 이상 남성에게는 이익이 없었습니다. 정기적인 검사는 위양성 결과를 초래하여 불필요한 불안과 전립선 생검을 유발할 수 있습니다. 검사에 대한 결정은 환자와 의사 간의 공유 의사 결정을 통해 개별화되어야 합니다.

높은 PSA 수치는 무엇을 의미하나요?

PSA 수치가 높다고 해서 반드시 전립선암을 의미하는 것은 아닙니다. PSA 수치가 높게 나오는 일반적인 비암성 원인으로는 양성 전립선 비대증(BPH), 급성 전립선염, 요로 감염, 최근의 전립선 시술 등이 있습니다. 비뇨의학과 의사는 전립선 생검을 권고하기 전에 나이, 전립선 크기, 시간에 따른 PSA 추세, 임상 소견 등을 종합적으로 고려하여 PSA 수치를 평가할 것입니다. PSA 수치가 높은 남성 중 상당수는 암이 없습니다.

PSA 검사의 위험은 다음과 같습니다.

The main risks of PSA screening stem from false positive results. A falsely elevated PSA may lead to a prostate biopsy, which carries risks including pain, hematuria (blood in urine), hematospermia (blood in semen), and infection. If biopsy leads to unnecessary treatment for indolent (non-harmful) cancer, additional risks include erectile dysfunction and urinary incontinence from surgery or radiation. Pre-biopsy MRI now spares many men a biopsy they would previously have undergone, which reduces this harm.

PSA 검사는 몇 살 때부터 시작해야 하나요?

Current evidence supports considering PSA screening in men aged 55–69 after an informed discussion with a doctor about the potential benefits and harms. Men with higher risk – such as those with a first-degree relative with prostate cancer or men of African descent – may benefit from starting discussions earlier, around age 40–45. Men aged 70 and above generally do not benefit from PSA screening according to current guidelines.

고지 사항: 이 콘텐츠는 방콕병원 본원의 공인 비뇨기과 전문의인 소라위 위라소폰(Soarawee Weerasopone) 박사가 작성하고 검토했습니다. 교육 목적으로만 제공되며 의학적 조언에 해당하지 않습니다. 개인 메시징 채널을 통해 의학적 조언, 진단 또는 처방은 제공되지 않습니다. 의학적 치료를 시작하기 전에 항상 자격을 갖춘 의료 전문가와 상담하십시오.

Medically written & reviewed by: Dr. Soarawee Weerasopone (Dr. Pom) — Board-Certified Urologist, Bangkok Hospital Headquarters, in urological practice since 2016. Fellowship: Robotic Surgery, Chang Gung Memorial Hospital, Taiwan (2019) · Observership: Endourology, Juntendo University Hospital, Tokyo (2022) · Research Scholar & Clinical Observer, Scott Department of Urology, Baylor College of Medicine, USA (2025–2026).

4개의 응답

ko_KR한국어

Dr. Soarawee Weerasopone — Urologist Bangkok에서 더 알아보기

지금 구독하여 계속 읽고 전체 아카이브에 액세스하세요.

계속 읽기